Effects of an oral contraceptive containing estetrol and dro
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
This study aimed to evaluate the effects of estetrol 15 mg/drospirenone 3 mg on ovarian function.

Single-center, randomized, open-label, parallel study in healthy young women with proven ovulatory cycles. Participants received either estetrol 15 mg/drospirenone 3 mg (E4/DRSP) (n=41) or ethinylestradiol 20 µg/drospirenone 3 mg (EE/DRSP) (n=41) in a 24/4-day regimen for 3 consecutive cycles. Follicular size and endometrial thickness were measured by transvaginal ultrasound every three days in cycles 1 and 3. Blood was sampled for hormone analysis. Ovarian function expressed as Hoogland score was based on follicular size, serum estradiol (E2) and progesterone (P) concentrations. Ovulation was defined as a ruptured follicle-like structure greater than 13 mm with serum E2 concentrations greater than 100 pmol/L and serum P concentrations greater than 5 nmol/L. They assessed return of ovulation after treatment cessation, and safety throughout the study.

Results:
-- None of the participants ovulated with E4/DRSP use, while one participant ovulated once and one participant ovulated twice during EE/DRSP treatment.

-- Most participants had a Hoogland score of 1 (no ovarian activity) in cycle 1 (85.0% and 82.9% of participants on E4/DRSP and EE/DRSP, respectively) and in cycle 3 (65.8% and 83.8%, respectively).

-- E4/DRSP suppressed follicle-stimulating hormone and luteinizing hormone to a lesser extent than E4/DRSP, whereas both treatments comparably suppressed E2 and P and endometrial thickness.

-- Return of ovulation occurred, on average, 15.5 days after E4/DRSP treatment discontinuation. E4/DRSP was safe and well-tolerated.

Conclusively, E4 15 mg/ DRSP 3 mg results in adequate ovulation inhibition and ovarian function suppression, comparable to a marketed combined oral contraceptive containing EE/DRSP.

Source: https://www.sciencedirect.com/science/article/pii/S0010782421000585?dgcid=rss_sd_all
Like
Comment
Share